These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 22284901)

  • 1. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
    Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
    Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
    Schmajuk G; Schneeweiss S; Katz JN; Weinblatt ME; Setoguchi S; Avorn J; Levin R; Solomon DH
    Arthritis Rheum; 2007 Aug; 57(6):928-34. PubMed ID: 17665462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
    Yazici Y; Shi N; John A
    Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.
    Bonafede M; Johnson BH; Shah N; Harrison DJ; Tang D; Stolshek BS
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP279-SP285. PubMed ID: 30020740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of drug use in rheumatoid arthritis.
    Bérard A; Solomon DH; Avorn J
    J Rheumatol; 2000 Jul; 27(7):1648-55. PubMed ID: 10914846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
    McBride S; Sarsour K; White LA; Nelson DR; Chawla AJ; Johnston JA
    J Rheumatol; 2011 Oct; 38(10):2141-9. PubMed ID: 21844154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lag time between onset of symptoms and access to rheumatology care and DMARD therapy in a cohort of patients with rheumatoid arthritis.
    Hernández-García C; Vargas E; Abásolo L; Lajas C; Bellajdell B; Morado IC; Macarrón P; Pato E; Fernández-Gutiérrez B; Bañares A; Jover JA
    J Rheumatol; 2000 Oct; 27(10):2323-8. PubMed ID: 11036824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
    Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
    J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
    Khanna R; Smith MJ
    Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.
    Carli C; Ehlin AG; Klareskog L; Lindblad S; Montgomery SM
    Ann Rheum Dis; 2006 Aug; 65(8):1102-5. PubMed ID: 16322085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Descriptive study of the use of DMARD in patients with rheumatoid arthritis or persistent arthritis who start drug treatment in Spain (FIRST)].
    Blanco FJ; Ballina J; Carbonell J; Martín-Mola E; Tornero J; Ramírez E; Galván J
    Reumatol Clin; 2011; 7(2):88-93. PubMed ID: 21794790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.